You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1 blockade

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

Nausea With Vomiting Chemo-Induced Trial in Wuhan (Ondansetron every 3 weeks, Aprepitant, Dexamethasone)

Not yet recruiting
  • Nausea With Vomiting Chemotherapy-Induced
  • Ondansetron every 3 weeks
  • +3 more
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Oct 8, 2023

Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)

Not yet recruiting
  • Endometrial Neoplasms
  • Endometrial Cancer
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System
Mar 21, 2023

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)

Recruiting
  • Rectal Neoplasms
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Jan 25, 2023

Unmethylated Glioblastoma Trial in Saint Louis (Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation

Not yet recruiting
  • Unmethylated Glioblastoma
  • Personalized Neoantigen DNA vaccine
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 14, 2023

Merkel Cell Carcinoma Trial in Philadelphia (Pembrolizumab)

Not yet recruiting
  • Merkel Cell Carcinoma
  • Philadelphia, Pennsylvania
    Penn Medicine
Aug 9, 2022

Oral Squamous Cell Carcinoma Trial in Wuhan (Camrelizumab, Camrelizumanb plus TPF)

Active, not recruiting
  • Oral Squamous Cell Carcinoma
  • Wuhan, Hubei, China
    Hospital of Stomatology, Wuhan University
Aug 17, 2022

NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

Recruiting
  • NSCLC
  • NK510
  • Tislelizumab，atezolizumab or sugemalimab
  • Nanjing, Jiangsu, China
    General Hospital of Eastern Theater Command
Oct 23, 2023

Non Small Cell Lung Cancer Trial in West Los Angeles (Tazemetostat)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • West Los Angeles, California
    VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Jul 21, 2022

Esophageal Squamous Cell Carcinoma Trial (Decitabine plus Penpulimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Decitabine plus Penpulimab
  • (no location specified)
Feb 23, 2022

Acute Myeloid Leukemia Trial in Atlanta (Fludarabine, Melphalan, Pembrolizumab)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Atlanta, Georgia
  • +1 more
Sep 7, 2022

NSCLC Trial in Melbourne, London (Pembrolizumab, Radiotherapy (SABR))

Completed
  • Non-small Cell Lung Cancer
  • Melbourne, Victoria, Australia
  • +1 more
May 23, 2022

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

PD-1 Blockade Plus Platinum-based Chemotherapy in EGFR Sensitive

Completed
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 9, 2022

    Solid Tumor Trial in Chicago (Stereotactic body radiotherapy (SBRT), Pembrolizumab)

    Active, not recruiting
    • Solid Tumor
    • Chicago, Illinois
      University of Chicago
    Mar 14, 2022

    Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma Trial in Shanghai (radiation, combination product, drug)

    Not yet recruiting
    • Liver Cancer
    • +4 more
    • intensity-modulated radiotherapy
    • +5 more
    • Shanghai, China
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
    Apr 20, 2022

    PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging

    Completed
    • Non-small Cell Lung Cancer (NSCLC)
      • Nîmes, France
        Jean-Paul BEREGI
      Jan 25, 2023

      Follicular Lymphoma Trial in Saint Louis (biological, drug, procedure)

      Suspended
      • Follicular Lymphoma
      • Personalized tumor vaccine
      • +6 more
      • Saint Louis, Missouri
        Washington University School of Medicine
      Nov 9, 2021

      Cutaneous Squamous Cell Carcinoma, Advanced Cancer Trial in Boston (Cemiplimab, Everolimus, Sirolimus)

      Recruiting
      • Cutaneous Squamous Cell Carcinoma
      • Advanced Cancer
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Jan 19, 2023

      Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer Trial in Guangzhou (PD-1 inhibitor, concurrent

      Recruiting
      • Anal Canal Cancer Stage III
      • +3 more
      • PD-1 inhibitor
      • concurrent chemoradiotherapy
      • Guangzhou, Guangdong, China
        The Sixth Affiliated Hospital of Sun Yat-sen University
      May 10, 2022

      Nasopharyngeal Carcinoma Trial in Guangzhou (Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab,

      Not yet recruiting
      • Nasopharyngeal Carcinoma
      • Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
      • Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
      • Guangzhou, Guangdong, China
        Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
      Apr 18, 2022

      Advanced or Unresectable Melanoma Progressing After PD1 Blockade Trial in Norway, United States (ONCOS-102, Cyclophosphamide,

      Completed
      Has Results
      • Advanced or Unresectable Melanoma Progressing After PD1 Blockade
      • ONCOS-102
      • +2 more
      • Baltimore, Maryland
      • +3 more
      Oct 11, 2021

      Metastatic Malignancy Trial in Houston (Atezolizumab, Tiragolumab)

      Not yet recruiting
      • Metastatic Malignancy
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 19, 2022

      Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

      Not yet recruiting
      • Colorectal Cancer Stage IV
      • +2 more
      • (no location specified)
      Jun 19, 2022